The Future of
Drug Discovery is Here.
Axcelead accelerates the discovery and development of high-value therapeutic candidates for the preclinical stage leading to human clinical trials. We leverage our proprietary end-to-end platform to enable our biotechnology and pharmaceutical partners to deliver benefits to patients around the world.
Who We Are
Axcelead is your trusted drug discovery and development partner.
We were formed in 2017 as a Takeda spin-out with a singular vision in mind – to support healthcare innovation as the world’s most trusted drug discovery solutions provider. We bring our vision to life by harnessing our expertise and proven track record of success in small molecule, cell therapy and immune-oncology drug discovery to our partners to advance and improve their drug pipelines.
What We Do
Oncology, immunology, neuroscience drug discovery and so much more.
At Axcelead, we are focused on accelerating the discovery and development of high-value drug classes through our end-to-end platform, enabling our biotechnology and pharmaceutical partners to deliver benefit to patients around the world.
Client Outcomes
We are your trusted partner.
At Axcelead, we have an aggressive mission to become the most trusted drug development solutions provider to leading biotechnology and pharmaceutical companies. Our wealth of expertise and knowledge stems from our robust client base, with over 100 facilities including pharmaceutical companies, venture companies and academia utilizing its services.
Our current partners in the US consist of cutting-edge companies developing new and proven drug candidates and modalities for oncology, immunology and neuroscience indications.
Success Rate
Achievement Rate
*LG/LO: Lead generation and lead optimization
Axcelead consistently demonstrates higher screening hit rates and project success rates compared to industry standards. These results are driven by expert researchers with extensive pharmaceutical R&D experience who leverage cutting-edge platforms to support our clients’ drug discovery. We also place great importance on communication, earning client trust and a high rate of repeat business by providing tailored solutions to their diverse challenges.
News
Our latest news and press releases.
A paper by researcher Hitaka of the Pharmacology Business Unit has been published in the International Journal of Obesity.
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison Publication...
Nissan Chemical and Axcelead DDP Enter into License Agreement for DNA-Encoded Library (DEL)
Tokyo and Fujisawa, Japan – February 24, 2026 – Nissan Chemical Corporation (Headquarter: Tokyo, Japan;...
Research article on advanced mass spectrometry analysis of disease-associated Asn-linked glycoconjugates in NGLY1 deficiency has been published
Structural characterization and insights into the formation of N-acetylglucosaminylasparagine and its derivatives in NGLY1-deficient models and patients...